Population Pharmacokinetic Modeling of Subcutaneously Administered Etanercept in Patients with Psoriasis
- 1 December 2004
- journal article
- research article
- Published by Springer Nature in Journal of Pharmacokinetics and Pharmacodynamics
- Vol. 31 (6) , 463-490
- https://doi.org/10.1007/s10928-005-5912-0
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- Etanercept as Monotherapy in Patients with PsoriasisNew England Journal of Medicine, 2003
- Population pharmacokinetic and pharmacodynamic modeling of etanercept using logistic regression analysisClinical Pharmacology & Therapeutics, 2003
- New Treatments for PsoriasisNew England Journal of Medicine, 2001
- Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trialThe Lancet, 2000
- The Pharmacokinetics of Etanercept in Healthy VolunteersAnnals of Pharmacotherapy, 2000
- Cytokines in psoriasisInternational Journal of Dermatology, 1999
- Etanercept Therapy in Rheumatoid ArthritisAnnals of Internal Medicine, 1999
- A Trial of Etanercept, a Recombinant Tumor Necrosis Factor Receptor:Fc Fusion Protein, in Patients with Rheumatoid Arthritis Receiving MethotrexateNew England Journal of Medicine, 1999
- Xpose—an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEMComputer Methods and Programs in Biomedicine, 1998
- POPULATION-BASED EPIDEMIOLOGIC STUDY OF PSORIASIS WITH EMPHASIS ON QUALITY OF LIFE ASSESSMENTDermatologic Clinics, 1996